Cingulate Inc
CING3.540USD
+0.020+0.57%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
17.31MMarket Cap
LossP/E TTM
More Details of Cingulate Inc Company
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Company Info
Ticker SymbolCING
Company nameCingulate Inc
IPO dateOct 07, 2021
CEOMs. Jennifer L. Callahan
Number of employees13
Security typeOrdinary Share
Fiscal year-endOct 07
Address1901 W. 47Th Place
CityKANSAS CITY
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code66205
Phone19139422300
Websitehttps://www.cingulate.com/
Ticker SymbolCING
IPO dateOct 07, 2021
CEOMs. Jennifer L. Callahan
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Dr. Matthew N. (Matt) Brams, M.D.
Dr. Matthew N. (Matt) Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Nilay Patel, J.D.
Mr. Nilay Patel, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Commonwealth Financial Network
2.15%
Werth Family Investment Associates LLC
1.75%
The Vanguard Group, Inc.
0.63%
Susquehanna International Group, LLP
0.59%
Geode Capital Management, L.L.C.
0.57%
Other
94.31%
Shareholders
Shareholders
Proportion
Commonwealth Financial Network
2.15%
Werth Family Investment Associates LLC
1.75%
The Vanguard Group, Inc.
0.63%
Susquehanna International Group, LLP
0.59%
Geode Capital Management, L.L.C.
0.57%
Other
94.31%
Shareholder Types
Shareholders
Proportion
Investment Advisor
4.09%
Corporation
1.81%
Investment Advisor/Hedge Fund
0.57%
Research Firm
0.38%
Venture Capital
0.20%
Hedge Fund
0.03%
Other
92.93%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
44
305.06K
5.93%
+1.66K
2025Q1
47
242.60K
6.03%
-49.04K
2024Q4
47
197.43K
6.15%
-35.64K
2024Q3
47
156.73K
4.97%
-40.96K
2024Q2
44
186.43K
34.55%
+67.80K
2024Q1
47
54.28K
18.74%
+25.73K
2023Q4
45
21.28K
29.79%
-7.47K
2023Q3
42
26.64K
41.94%
+1.78K
2023Q2
36
15.08K
30.98%
-2.19K
2023Q1
34
15.09K
32.03%
-921.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Commonwealth Financial Network
55.52K
1.31%
+12.50K
+29.05%
Mar 31, 2025
Werth Family Investment Associates LLC
97.99K
2.31%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
10.76K
0.25%
+8.76K
+438.54%
Mar 31, 2025
Geode Capital Management, L.L.C.
30.40K
0.72%
+3.08K
+11.26%
Mar 31, 2025
UBS Financial Services, Inc.
22.12K
0.52%
+9.92K
+81.34%
Mar 31, 2025
Quantum Private Wealth, LLC
10.00K
0.24%
+10.00K
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Date
Type
Ratio
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
